Permanent brachytherapy is one of those standard treatments for localized prostate cancer patients.
Biopsy confirms prostate cancer. Blood and urine of localized prostate cancer patients will be collected before and at different time points after permanent brachytherapy (1, 3, 6, and 12 months)
Age
30–90
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
\- Biopsy confirms prostate cancer
Localized Prostate Cancer, ≤cT3
No chemotherapy or Hormonal therapy before Permanent Brachytherapy
You may not be if
\- Unacceptable operative risk
Poor anatomy which in the opinion of the radiation oncologist could lead to a suboptimal implant (e.g.,large or poorly healed transurethral resection of the prostate (TURP) defect, large median lobe, large gland size).
Pathologically positive lymph nodes
Significant obstructive uropathy
Distant metastases
Use steroids regularly
The diagnosis was accompanied by immune-related diseases
Allergic constitution
Abnormal white blood cell and lymphocyte counts
Ever underwent other treatments for prostate cancer, such as chemotherapy or Hormonal therapy
Accompanied by other malignancies
Splenectomy
HIV positive
Receive an anti-infective vaccine for the last 6 months
Clareo Health | PD-L1-expressing Regulatory T Cells in Localized Prostate Cancer Patients Undergoing Iodine-125 Permanent Brachytherapy
